State Street SPDR S&P Pharmaceuticals ETF
XPH
79 hedge funds and large institutions have $172M invested in State Street SPDR S&P Pharmaceuticals ETF in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 11 closing their positions.
1.75% more ownership
Funds ownership: 38.12% → 39.88% (+1.8%)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0% less capital invested
Capital invested by funds: $172M → $172M (-$95.9K)
1% less funds holding
Funds holding: 80 → 79 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$4.53M |
| 2 |
JP Morgan Chase
New York
|
+$3.94M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.15M |
| 4 |
Morgan Stanley
New York
|
+$997K |
| 5 |
OLA
Oliver Luxxe Assets
Gladstone,
New Jersey
|
+$961K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.98M |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.44M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.57M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.09M |
| 5 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$1.03M |
XPH Hedge Fund Activity: Q3 2017 in Review
79 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2017, worth a combined $172M — down 0.06% from $172M a quarter earlier.
Fund positioning in XPH was balanced in Q3 2017: 11 funds opened new positions, 11 closed out, 21 added to existing stakes and 20 trimmed.
The largest buyer was Two Sigma Securities, adding an estimated $4.53M. The largest seller was UBS Group, cutting an estimated $3.98M.
- 79 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2017, down from 80 in Q2 2017.
- Funds reported $172M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2017, down 0.06% quarter-over-quarter.
- 11 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2017 and 11 closed out, a net change of 0 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2017 was Two Sigma Securities, an estimated $4.53M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2017 was UBS Group, an estimated $3.98M sold.
Based on aggregated 13F filings for Q3 2017.